| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 58.19% | 69.42% | 63.77% | 55.31% | 62.07% | 83.37% | 79.50% |
| Operating Margin | 12.58% | 0.10% | 9.65% | -11.15% | -18.41% | -7.68% | 7.92% | 17.54% | 16.02% | 15.61% | 42.84% | 35.74% |
| EBITDA Margin | 22.92% | 11.12% | 21.93% | 6.86% | 3.45% | 13.73% | 29.52% | 34.28% | 31.81% | 32.98% | 51.89% | 42.67% |
| Net Margin | 8.87% | -3.01% | 3.86% | -15.14% | -19.71% | -10.82% | 2.95% | 7.69% | -0.61% | 3.06% | 20.14% | 51.36% |
| Current Ratio | 2.71 | 2.72 | 3.57 | 3.46 | 3.68 | 2.17 | 3.04 | 0.92 | 3.35 | 3.22 | 16.38 | 15.38 |
| Quick Ratio | 2.19 | 2.02 | 2.81 | 2.40 | 2.74 | 1.39 | 2.26 | 0.68 | 2.39 | 2.40 | 15.24 | 14.81 |
| Debt / Equity | 0.57 | 0.79 | 0.66 | 0.91 | 0.86 | 0.95 | 0.87 | 0.36 | 0.42 | 0.00 | 0.71 | 0.79 |
| ROE | 14.49% | -4.59% | 4.34% | -15.27% | -12.76% | -11.52% | 2.86% | 7.85% | -0.62% | 2.32% | 9.60% | 20.57% |
| ROA | 5.44% | -1.44% | 2.08% | -6.30% | -5.52% | -4.89% | 1.33% | 3.60% | -0.26% | 1.22% | 5.39% | 10.90% |
| Asset Turnover | 0.61 | 0.48 | 0.54 | 0.42 | 0.28 | 0.45 | 0.45 | 0.47 | 0.43 | 0.40 | 0.27 | 0.21 |
| Book Value / Share | 25.47 | 20.90 | 23.79 | 19.29 | 26.51 | 16.36 | 17.67 | 16.76 | 15.13 | 14.66 | 13851.52 | 12.65 |
ANI Pharmaceuticals Inc. is a diversified biopharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals. It specializes in a range of dosage forms, including liquid, powder, oral solid-dose products, injectables, softgel capsules, semi-solids, topicals, and controlled substances. The company operates through key segments: Rare Disease, featuring novel therapeutics in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, such as Purified Cortrophin Gel, ILUVIEN, and YUTIQ; Generics, leveraging R&D expertise and U.S.-based manufacturing for products like Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone, and Vancomycin; and Established Brands. ANI Pharmaceuticals Inc. focuses on areas like narcotics, oncolytics, hormones, steroids, and complex formulations including extended-release and combination products. Primarily serving the United States and Canada, it emphasizes high-quality therapeutics through operational excellence and North American manufacturing capabilities. Founded in 2001 and headquartered in Baudette, Minnesota, ANI Pharmaceuticals Inc. plays a vital role in addressing patient needs across specialized pharmaceutical markets.